GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib ...

Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ETCompany ParticipantsEmma Walmsley - Chief ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

Deutsche Bank analyst Emmanuel Papadakis downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK plc announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecologic cancers may experience. The survey, which was conducted by ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...